Dynavax Technologies CORP Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Dynavax Technologies Corp. President & COO David F. Novack exercised options and sold 114,000 shares of common stock under a pre-arranged 10b5-1 trading plan.
DYNAVax Technologies' SVP and CFO, Kelly MacDonald, reported accelerated vesting of performance and restricted stock units tied to the company's merger agreement with Sanofi.
Joseph Anthony Metzinger, Dynavax Technologies Corp.'s VP, Chief Accounting Officer, reported accelerated RSU vesting and subsequent stock transactions following a merger agreement with Sanofi.
Dynavax Technologies' President & COO, David F. Novack, reported significant stock acquisitions from accelerated vesting and option exercises, alongside sales, following the company's merger agreement with Sanofi.
Dynavax Technologies SVP John L. Slebir's performance and restricted stock units accelerated vesting on December 23, 2025, in connection with a merger agreement with Sanofi.
Dynavax Technologies CEO Ryan Spencer reported accelerated vesting of performance and restricted stock units in connection with the company's merger agreement with Sanofi.
DYNAVAX Technologies Director Scott Myers acquired 3,800 shares of common stock on the open market, signaling confidence in the company's future.
Deep Track Biotechnology Master Fund and affiliates sold over 2 million shares of Dynavax Technologies common stock in pre-planned transactions.
Dynavax Technologies Corp. Director Lauren P. Silvernail has acquired 1,439 restricted stock units and 7,125 stock options as part of a compensation grant, as reported in a recent SEC Form 4 filing.
Dynavax Technologies Corp. Director Daniel L. Kisner has reported the acquisition of 5,758 restricted stock units and 28,500 stock options, granted as compensation.
Dynavax Technologies Corp. Director Scott Myers acquired 5,758 restricted stock units and 28,500 stock options on June 11, 2025, aligning his interests further with shareholders.
Dynavax Technologies Corp. Director Peter R. Paradiso was granted 5,758 restricted stock units and 28,500 stock options on June 11, 2025, as part of his compensation.
DYNAVAX Technologies Corp. Director Emilio Emini was granted 1,439 restricted stock units and 7,125 stock options on June 11, 2025, increasing his direct beneficial ownership in the company.
Dynavax Technologies Corp. Director Elaine Sun has reported the acquisition of 5,758 restricted stock units and 28,500 stock options, increasing her beneficial ownership in the company.
Dynavax Technologies Corp. Director Brent MacGregor was granted 5,758 restricted stock units and 28,500 stock options, increasing his beneficial ownership in the company.
Dynavax Technologies Corp. Director Francis Cano has increased his beneficial ownership through the acquisition of 5,758 restricted stock units and 28,500 stock options, as reported in a recent SEC Form 4 filing.
Joseph Metzinger, VP and Chief Accounting Officer of Dynavax Technologies, reports the acquisition of stock options and restricted stock units (RSUs) on May 12, 2025.
David F. Novack, President & COO of Dynavax Technologies Corp, reports the sale and acquisition of common stock and stock options on March 24, 2025, pursuant to a pre-arranged 10b5-1 trading plan.
Dynavax Technologies' President and COO, David Novack, sold 14,020 shares of common stock on March 18, 2025, under a pre-arranged 10b5-1 trading plan.
Dynavax Technologies' President and COO, David Novack, sold 32,764 shares of common stock on March 7, 2025, at a weighted average price of $14.39.
John L. Slebir, SVP General Counsel of Dynavax Technologies, reports the vesting of restricted stock units and subsequent tax withholding.
Robert Janssen, SVP and CMO of Dynavax Technologies, reports the vesting of restricted stock units and subsequent tax withholding.
Kelly MacDonald, SVP and CFO of Dynavax Technologies, reports the vesting of restricted stock units and subsequent stock transactions.
Dynavax Technologies CEO Ryan Spencer reports the vesting and subsequent sale of restricted stock units to cover tax obligations.
David Novack, President & COO of Dynavax Technologies, reports the acquisition and disposal of common stock and restricted stock units on February 18, 2025.
CEO Ryan Spencer reports acquisition and disposal of Dynavax Technologies Corp stock and derivative securities.
John L. Slebir, SVP General Counsel of Dynavax Technologies Corp, reports acquisition and disposal of common stock and derivative securities, including stock options and restricted stock units, on February 13, 2025.
David Novack, President & COO of Dynavax Technologies, reports acquisition and disposal of common stock and derivative securities.
Kelly MacDonald, CFO of Dynavax Technologies, reports the vesting of restricted stock units, stock option grants, and related tax withholding.
Robert Janssen, SVP and CMO of Dynavax Technologies, reports the acquisition and disposal of Dynavax stock and derivative securities on February 13, 2025.